Formally endorses resources produced by external organisations that support the implementation of NICE guidance and the use of quality standards.
The information below provides a summary of known issues and upcoming changes related to NICE Evidence Services. This information will be updated...
This guidance evaluates new, innovative medical devices and diagnostics. It looks at medical technologies that: deliver treatment - like those...
An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE for use in the Cancer Drugs Fund (CDF).
Advice on the use of MR-proADM test for use with clinical deterioration scores in cases of suspected infection to aid local decision making
Advice on the use of superDimension Navigation System to help diagnostic sampling of peripheral lung lesions to aid local decision making
How to apply to become the new chief executive of NICE
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
Information, meeting dates and minutes of the medical technologies advisory committee
Details, meeting dates and minutes of the independent technology appraisal committees
Find out more about the NICE Medical Technologies Advisory Committee members by reading their biographies. Professor Peter Groves Chair About
How we select the subjects for development into information, advice and guidance
Jobs at NICE. Includes current vacancies, roles, location and salary information.
Everything NICE has said on preventing and managing foot problems in children, young people and adults with type 1 or 2 diabetes in an interactive flowchart
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults
Apply to chair a NICE social care guideline committee
Everything NICE has said on harmful sexual behaviour among children and young people (under 18s or under 25s with special educational needs or a disability) in an interactive flowchart.
Everything NICE has said on investigating and managing dyspepsia and gastro-oesophageal reflux disease in an interactive flowchart
This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.
Biographies of the NICE senior management team and minutes of their meetings
Everything NICE has said on cerebral palsy in an interactive flowchart
Everything NICE has said on eye conditions in an interactive flowchart
Everything NICE has said on diagnosing and managing Parkinson's disease in adults in primary and secondary care in an interactive flowchart
Everything NICE has said on assessing and managing motor neurone disease in adults in an interactive flowchart
Evidence-based recommendations on the EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing
Everything NICE has said on musculoskeletal conditions in an interactive flowchart
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.
NICE quality standards set out priority areas for quality improvement in health and social care.
Everything NICE has said on shared decision-making and processes to optimise medicines and support adherence in an interactive flowchart
Everything NICE has said on triage, assessment, investigation and management of head injury in infants, children and adults in an interactive flowchart
Information for developers of digital therapies about submitting a product to the IAPT programme
This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.
Everything NICE has said on familial hypercholesterolaemia in an interactive flowchart
Draft guidance published today (3 October 2019) by NICE does not recommend atezolizumab (also called Tecentriq and made by Roche) for treating people with a type of breast cancer called triple A breast cancer that has spread to other parts of the body and who can’t have surgery to remove it.
Everything NICE has said on diagnosing and managing lower limb peripheral arterial disease in an interactive flowchart
A guide to intermediate care services that provide support for a short time to help you recover and increase your independence
Guide for young people and their families about being assessed for autism
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults
Everything NICE has said on diagnosing and managing the epilepsies in adults and children in primary and secondary care in an interactive flowchart
The guideline covers diagnosing, treating and managing epilepsy and seizures in children, young people and adults in primary and secondary care. It offers best practice advice on managing epilepsy to improve health outcomes so that people with epilepsy can fully participate in daily life.
Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources. Previously known as the forward planner.
Public Health Advisory Committees (PHACs) are the standing committees responsible for the development of NICE public health guidance. Each PHAC...
NICE indicators. NM03 epilepsy guidance.
Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart
Access and insight for international organisations into the way we work. Learn about our products and the processes and methods we use to develop them.